Trial Profile
AMP: Single arm, phase I/II study to evaluate the six month progression free survival of AMG 102 and panitumumab in recurrent Glioblastoma Multiforme (GBM)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jun 2016
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Rilotumumab (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 12 Jul 2011 New trial record